Analysis of mRNA Flu Vaccine Risks

Uh, we did a risk-benefit analysis of what's

called

Fluceava, Moderna's mRNA flu shot.

This is now peer-reviewed in the Journal of Independent Medicine,

and here's what we found according to the FDA's own data.

To prevent one flu hospitalization with

Fluceava, 5,000 people had to get the vaccine, 4,000

people had to suffer an adverse event, about 300 had to suffer

a disabling grade three reaction preventing daily activity,

and two people had to die. And so this is an extreme

risk-benefit profile. I don't think I've ever seen a worse one

in my life,

and unfortunately, that's being rolled out to ages over 50.

I haven't seen, uh, risk disclosures for the

advertisements of this shot, and so that's, that's very concerning

to me. But